Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BRII-693
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Brii Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Brii Bio will acquire exclusive global rights for the development and commercialization of QPX9003 (BRII-693), a novel synthetic lipopeptide in development for the treatment of MDR/XDR gram-negative bacterial infections, to expand from its existing right...
Brand Name : QPX9003
Molecule Type : Peptide
Upfront Cash : $24.0 million
June 25, 2023
Lead Product(s) : BRII-693
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Brii Biosciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Xeruborbactam,QPX2015
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Shionogi
Deal Size : $140.0 million
Deal Type : Acquisition
Details : Through the acquisition, Shionogi extends its infectious disease innovation platform with the access to a novel investigational beta-lactamase inhibitor, QPX7728 (xeruborbactam), which is being advanced clinically for infections caused by drug-resistant ...
Brand Name : QPX7728
Molecule Type : Small molecule
Upfront Cash : $100.0 million
June 25, 2023
Lead Product(s) : Xeruborbactam,QPX2015
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Shionogi
Deal Size : $140.0 million
Deal Type : Acquisition
Lead Product(s) : Xeruborbactam,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ORAvance (Xeruborbactam) an orally-administered combination product that delivers xeruborbactam to treat infections that occur in outpatient and community setting caused by drug-resistant gram-negative bacteria.
Brand Name : ORAvance
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 17, 2022
Lead Product(s) : Xeruborbactam,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Xeruborbactam,QPX2014
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : New clinical data for β-lactamase inhibitor xeruborbactam (formerly QPX7728) and synthetic lipopeptide QPX9003, represent new potential therapies for patients with drug-resistant infections – notably carbapenem-resistant Acinetobacter, Pseudomonas, an...
Brand Name : QPX7728
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 21, 2022
Lead Product(s) : Xeruborbactam,QPX2014
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : QPX9003
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The resulting new lipopeptide QPX9003 is pharmacologically distinct from existing polymyxin drugs with a superior safety and efficacy against experimentally-induced lung infections caused by Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella ...
Brand Name : QPX9003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2022
Lead Product(s) : QPX9003
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Xeruborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : BARDA
Deal Size : $15.0 million
Deal Type : Agreement
Details : Qpex exercised a $15 million option from the BARDA, to support the advancement of its anti-infective portfolio which includes OMNIvance, ORAvance and QPX9003, into the clinic intended to comprehensively address patient needs in both the inpatient and out...
Brand Name : QPX7728
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2021
Lead Product(s) : Xeruborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : BARDA
Deal Size : $15.0 million
Deal Type : Agreement
Lead Product(s) : Xeruborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections
Details : The Phase 1 study will investigate the safety and pharmacokinetics of QPX7728 alone following single and multiple intravenous doses, and in combination with a beta-lactam antibiotic in healthy adult subjects.
Brand Name : QPX7728
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 03, 2020
Lead Product(s) : Xeruborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?